[The efficacy of the multienzyme preparation Wobe-Mugos E in lymphoproliferative diseases].

Abstract

The drug Wobe-Mugos E was prescribed to patients with chronic lymphoid leukosis and multiple myeloma during and following the administration of chemotherapy treatment, 3 tablets on a three-times daily schedule 30 to 45 minutes before meals for 2 to 4 weeks. A positive effect was manifested by improvement in morphofunctional properties of erythrocytes, detoxicating and antioxidant effects. There were no cases of intolerability or side effects of the drug in the examined patients.

• Authors: M Iu Kolomoiets', M P Antofiĭchuk
• Journal: Likars'ka sprava (Lik Sprava) Issue 4 Pg. 150-4 (Jun 1999) ISSN: 1019-5297 [Print] Ukraine
• Vernacular Title: Efektyvnist' polienzymnoho preparatu "Vobe-Mugos E" pry limfoproliferatyvnykh zakhvoriuvanniakh.
• PMID: 10476670 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Drug Combinations
• Peptide Hydrolases
• wobe

Topics

• Adjuvants, Immunologic (adverse effects, therapeutic use)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Drug Combinations
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Middle Aged
• Multiple Myeloma (drug therapy)
• Peptide Hydrolases (adverse effects, therapeutic use)